Joseph deBethizy
Directeur/Membre du Conseil chez ARGENX SE
Fortune : 168 792 $ au 30/04/2024
Provenance du réseau au premier degré de Joseph deBethizy
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
29
| Public Company | Pharmaceuticals: Other | 29 |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.
23
| Extinct | Pharmaceuticals: Other | 23 |
| Public Company | Biotechnology | 14 | |
11
| Public Company | Biotechnology | 11 |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.
9
| Subsidiary | Biotechnology | 9 |
Saniona A/S
 Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.
7
| Subsidiary | Miscellaneous Commercial Services | 7 |
Proterris, Inc.
 Proterris, Inc. Pharmaceuticals: MajorHealth Technology Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA.
6
| Holding Company | Pharmaceuticals: Major | 6 |
| Public Company | Pharmaceuticals: Major | 5 | |
Albumedix Ltd.
 Albumedix Ltd. BiotechnologyHealth Technology Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million.
4
| Subsidiary | Biotechnology | 4 |
Albumedix A/S
 Albumedix A/S Pharmaceuticals: MajorHealth Technology Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark.
2
| Private Company | Pharmaceuticals: Major | 2 |
Rigontec GmbH
 Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Contera Pharma ApS
 Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Joseph deBethizy via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| BECTON, DICKINSON AND COMPANY | Medical Specialties | Chief Administrative Officer Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Director of Finance/CFO Comptroller/Controller/Auditor Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| PROCTER & GAMBLE COMPANY | Household/Personal Care | Director/Board Member Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| BELLICUM PHARMACEUTICALS, INC. | Biotechnology | Director of Finance/CFO Director/Board Member Corporate Officer/Principal | |
ZP Opco, Inc.
 ZP Opco, Inc. Pharmaceuticals: MajorHealth Technology ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PELOTON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| J.E.M. CAPITAL INC | Financial Conglomerates | Director/Board Member Director/Board Member | |
| NURIX THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Investment Managers | Chief Executive Officer Chief Executive Officer | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
| EVOTEC SE | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
Roche Diagnostics GmbH
 Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor Corporate Officer/Principal Corporate Officer/Principal | |
| Boston College | College/University | Masters Business Admin Undergraduate Degree Undergraduate Degree | |
| University of London | College/University | Graduate Degree Doctorate Degree Graduate Degree | |
| University of Toronto | College/University | Doctorate Degree Undergraduate Degree Graduate Degree | |
| University of Wisconsin | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| ABLYNX | Biotechnology | Director/Board Member Chairman Corporate Officer/Principal | |
| DBV TECHNOLOGIES | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| University of Utrecht | College/University | Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
| Katholieke Universiteit Leuven | College/University | Corporate Officer/Principal Undergraduate Degree Doctorate Degree | |
| ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| SPEXIS AG | Pharmaceuticals: Major | Chief Operating Officer Chief Executive Officer | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| The National Health Museum | Director/Board Member Director/Board Member | ||
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Founder Founder | |
| VIVORYON THERAPEUTICS N.V. | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
JenaValve Technology GmbH
 JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Medical Specialties | Director of Finance/CFO Director/Board Member | |
NewBridge Pharmaceuticals FZ LLC
 NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Johnson & Johnson Pharmaceutical Group | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | ||
Caerus Consulting AS
 Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Chairman Director/Board Member Director/Board Member Director/Board Member | |
| AVALO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Aniona ApS
 Aniona ApS Medical/Nursing ServicesHealth Services Aniona ApS is a private company based in Ballerup, Denmark. Jørgen Drejer has been the CEOs since incorporation. The Danish company was founded by Thomas Feldthus, Anker Gunvald Lundemose, Claus Tycho Bræstrup, Jørgen Drejer. | Medical/Nursing Services | Founder Founder Founder Director/Board Member | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
EnBiotix, Inc.
 EnBiotix, Inc. Medical/Nursing ServicesHealth Services EnBiotix, Inc. operates as a late clinical-stage respiratory therapeutics company, which engages in deploying novel systems and synthetic biology technologies. It offers anti-persisters, engineered bacteriophage, tunable target degradation, and systems biology platform. Its pipeline includes ColiFin, EBX-001, EBX-002, and Linear Peptide Antibiotics. The company was founded by James J. Collins in 2012 and is headquartered in Boston, MA. | Medical/Nursing Services | Director of Finance/CFO Chief Executive Officer | |
| ALBIREO PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer General Counsel | |
| INITIATOR PHARMA A/S | Pharmaceuticals: Major | Chairman Founder Founder | |
California Life Sciences Association
 California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 22 |
| Danemark | 7 |
| Allemagne | 6 |
| France | 5 |
| Belgique | 4 |
Sectorielle
| Health Technology | 28 |
| Consumer Services | 13 |
| Finance | 4 |
| Commercial Services | 3 |
| Health Services | 3 |
Opérationnelle
| Director/Board Member | 692 |
| Corporate Officer/Principal | 204 |
| Independent Dir/Board Member | 173 |
| Chairman | 129 |
| Chief Executive Officer | 72 |
Relations les plus connectées
| Insiders | |
|---|---|
| Peter Hutt | 69 |
| Gunnar Magnus Modee Persson | 51 |
| Michael Barrett | 49 |
| G. Steven Burrill | 44 |
| Ralph Snyderman | 41 |
| Bo Jesper Hansen | 34 |
| Alan Dunton | 34 |
| Bruno Montanari | 30 |
| Julia Brown | 27 |
| Hubert Birner | 27 |
| Jørgen Drejer | 26 |
| Denis Lucquin | 26 |
| Ann Hanham | 26 |
| Holger N. Reithinger | 25 |
| Anker Gunvald Lundemose | 25 |
- Bourse
- Insiders
- Joseph deBethizy
- Connexions Sociétés